In vivo, GX-I7 led to an increase in peripheral lymphocyte counts and TILs when administered either in monotherapy or combination therapy with cyclophosphamide (CPA) or ICI (e.g., anti-PD-(L)1 or anti-CTLA-4 antibody), and showed anti-tumour efficacy in murine syngeneic tumour models [22]. The gene discussed is CTLA4; the disease is neoplasm.